Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital cuts Burberry price target

(Sharecast News) - RBC Capital Markets cut its price target on Burberry on Friday to 1,200p from 1,300p as it reduced FY26 EBIT estimates. The bank noted that Burberry shares have been weak, reversing all post 1H gains. This likely reflects fourth-quarter retail LFL expectations unlikely to show a sequential improvement, pushing back the potential recovery timeframe.

RBC cut its FY25 revenue estimate by 1% and its EBIT estimate to £5.2m from £5.7m. For FY26, it forecasts organic growth of 2% and £136m EBIT, which is 8% below its prior estimate.

The bank said its estimates are 3% below consensus revenue and 17% below consensus EBIT for FY26.

"Whilst Burberry is early in its turnaround, we believe it is pursuing the right strategy and Autumn/Winter '25 collection should start to address its price architecture offering some retail LFL support," RBC said.

It added that the strategy update from chief executive Joshua Schulman with FY25 results should offer "incremental insight into progress and next steps".

RBC rates the shares at 'outperform', speculative risk.

At 1050 GMT, the shares were down 1.2% at 816p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.